Sugi Predict

Sugi Predict / Compounds / SCHEMBL2406097

SCHEMBL2406097

SCHEMBL2406097

NCCC(O)C(c1ccccc1)(c1ccccc1)c1ccccc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNN4 O15554 3/20 0.46
▸ KIF11 P52732 9/20 0.42
▸ HTR2A P28223 2/20 0.39
▸ HTR2C P28335 2/20 0.39
▸ OPRK1 P41145 2/20 0.39
▸ KCNH2 Q12809 2/20 0.39
▸ ADRA1A P35348 1/20 0.39
▸ HRH1 P35367 2/20 0.35
▸ KCNA3 P22001 2/20 0.34
▸ CYP3A4 P08684 2/20 0.33
▸ TSHR P16473 2/20 0.33
▸ TAAR1 Q96RJ0 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ SLC22A1 O15245 1/20 0.33
▸ NR1I2 O75469 1/20 0.33
▸ GMNN O75496 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ TRPM2 O94759 1/20 0.33
▸ ABCB11 O95342 1/20 0.33
▸ EGFR P00533 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2405440 0.91 KCNN4 (0.44) KCNN4KIF11HTR2AHTR2COPRK1
SCHEMBL5577083 0.81 KCNN4 (0.41) KCNN4KIF11HTR2AHTR2COPRK1
SCHEMBL10586377 0.78 TAAR1 (0.38) KIF11KCNH2TAAR1LMNACYP1A2
SCHEMBL16416723 0.77 KCNN4 (0.45) KCNN4KIF11HTR2AHTR2COPRK1
SCHEMBL27824023 0.72 KCNN4 (0.53) KCNN4KIF11HTR2AHTR2COPRK1
SCHEMBL1701240 0.71 KCNN4 (0.53) KCNN4KIF11HTR2AHTR2COPRK1
SCHEMBL5967507 0.71 KCNN4 (0.49) KCNN4KIF11HTR2AHTR2COPRK1
SCHEMBL10586379 0.71 KIF11 (0.54) KIF11KCNH2SLC6A2SLC6A4SLC6A3
SCHEMBL32668806 0.69 HTR2A (0.65) KCNN4KIF11HTR2AHTR2COPRK1
SCHEMBL6655136 0.68 TAAR1 (0.41) KCNN4KIF11HTR2ATAAR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3215116-B1 A HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE UNIV OF THE SCIENCES IN PHILADELPHIA (US) 2020-09-30 — — EP disclosed
US-10265413-B2 High molecular weight biodegradable gelatin-doxorubicin conjugate UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) 2019-04-23 — — US disclosed
US-10005816-B2 Peptides and their use in food and beverage The Folger Coffee Company (US) 2018-06-26 — — US disclosed
US-20170354741-A1 HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) 2017-12-14 — — US disclosed
EP-3215116-A1 A HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE University of the Sciences in Philadelphia (US) 2017-09-13 — — EP disclosed
EP-2205624-B1 INSULINOTROPIC PEPTIDE SYNTHESIS USING SOLID AND SOLUTION PHASE COMBINATION TECHNIQUES CORDEN PHARMA COLORADO INC (US) 2016-09-07 — — EP disclosed
US-20160165916-A1 NOVEL PEPTIDES AND THEIR USE IN FOOD AND BEVERAGE The Folger Coffee Company 2016-06-16 — — US disclosed
WO-2016077083-A1 A HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) 2016-05-19 — — WO disclosed
US-20140343227-A1 Diketopiperazine Forming Dipeptidyl Linker LONZA AG (CH) 2014-11-20 — — US disclosed
US-8802819-B2 Diketopiperazine forming dipeptidyl linker LONZA LTD. (CH) 2014-08-12 — — US disclosed
US-20080004429-A1 Insulinotropic peptide synthesis using solid and solution phase combination techniques ROCHE PALO ALTO LLC 2008-01-03 — — US disclosed
WO-2007147816-A1 INSULINOTROPIC PEPTIDE SYNTHESIS F. HOFFMANN-LA ROCHE AG (CH) 2007-12-27 — — WO disclosed
EP-1856142-A1 SYNTHESIS OF PEPTIDE T-1249 USING PEPTIDE INTERMEDIATE FRAGMENTS F. Hoffmann-Roche AG (CH) 2007-11-21 — — EP disclosed
EP-1833843-A1 SYNTHESIS OF PEPTIDE T-20 USING PEPTIDE INTERMEDIATE FRAGMENTS F. HOFFMANN-LA ROCHE AG (CH) 2007-09-19 — — EP disclosed
US-20070213504-A1 Synthesis using peptide intermediate fragments ROCHE COLORADO CORPORATION 2007-09-13 — — US disclosed
US-20060276624-A1 Synthesis using peptide intermediate fragments ROCHE COLORADO CORPORATION 2006-12-07 — — US disclosed
US-20060173163-A1 Synthesis using peptide intermediate fragments ROCHE COLORADO CORPORATION 2006-08-03 — — US disclosed
WO-2006069729-A1 SYNTHESIS OF PEPTIDE T-1249 USING PEPTIDE INTERMEDIATE FRAGMENTS F. HOFFMANN-LA ROCHE AG (CH) 2006-07-06 — — WO disclosed
WO-2006069727-A2 SYNTHESIS OF PEPTIDE T-20 USING PEPTIDE INTERMEDIATE FRAGMENTS F. HOFFMANN-LA ROCHE AG (CH) 2006-07-06 — — WO disclosed
WO-2006069728-A1 SYNTHESIS OF PEPTIDE T-20 USING PEPTIDE INTERMEDIATE FRAGMENTS F. HOFFMANN-LA ROCHE AG (CH) 2006-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170354741-A1 HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE MMP2, DNASE1L3, DNASE1 KCNN4 4626/4885KIF11 905/4885HTR2A 2687/4885
US-10265413-B2 High molecular weight biodegradable gelatin-doxorubicin conjugate MMP2, DNASE1L3, DNASE1 KCNN4 4626/4885KIF11 905/4885HTR2A 2687/4885
US-20080004429-A1 Insulinotropic peptide synthesis using solid and solution phase combination techniques IAPP, GLP1R, GIPR KCNN4 3754/4885KIF11 2535/4885HTR2A 2685/4885
US-20140343227-A1 Diketopiperazine Forming Dipeptidyl Linker FAP, IAPP, DNPEP KCNN4 4354/4885KIF11 3584/4885HTR2A 2267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.